Medical device company Artivion (NYSE:AORT) missed Wall Street’s revenue expectations in Q4 CY2024 as sales rose 3.9% year on ...

Shares of medical device company Artivion (NYSE:AORT) fell 11.2% in the morning session after the company reported weak fourth-quarter 2024 results, as both revenue and EPS missed Wall Street's ...

Artivion (NYSE:AORT – Get Free Report) had its target price reduced by equities research analysts at Stifel Nicolaus from $33 ...

It's been a mediocre week for Artivion, Inc. ( NYSE:AORT ) shareholders, with the stock dropping 13% to US$25.42 in ...

Artivion, Inc. (NYSE:AORT – Get Free Report)’s stock price gapped down before the market opened on Tuesday following a dissappointing earnings announcement. The stock had previously closed at $27.85, ...

In the latest quarter, 4 analysts provided ratings for Artivion AORT, showcasing a mix of bullish and bearish perspectives. The following table summarizes their recent ratings, shedding light on ...

Stifel lowered the firm’s price target on Artivion (AORT) to $30 from $33 and keeps a Buy rating on the shares after Q4 consensus sales ...

The Kennesaw, Georgia-based company said it had a loss of 39 cents per share. Earnings, adjusted for one-time gains and costs, were less than 1 cent on a per-share basis. The biological medical device ...

Booking Holdings and Mizuho Financial are among the stocks that are now expensive. We sell different types of products and services to both investment professionals and individual investors. These ...

Greetings, and welcome to the Artivion Fourth Quarter and Year End 2024 Financial Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure ...

Artivion Inc. (AORT), with a market capitalization of $1.17 billion, reported its Q4 2024 earnings, revealing a revenue of $97.3 million, which fell short of the forecasted $100.82 million.